Skip to content

Teva Pharmaceutical Industries

US · TEVA #471 by market cap Listed 1970
39.18 +0.05 +0.13%
Live - 5344 symbols - heartbeat 176s ago · 2026-10-08 08:25
Pre-market 38.81 -0.94%
After-hours 39.18 0.00%
Overnight 38.80 -0.97%
Market cap
45.70B
P/B
5.89
EPS
1.21
Reader sentiment Are you bullish or bearish on TEVA?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
    GlobeNewswire · 2026/9/16
  • Company notice
    TEVA PHARMACEUTICAL INDUSTRIES | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)
    SEC · 2024/4/9
  • Company notice
    Teva Pharmaceutical Industries | 3: Initial statement of beneficial ownership of securities-Officer McAvoy David R.
    SEC · 2024/3/6
  • Teva Pharmaceutical Industries(TEVA.US) Director Sells US$14.36 Million in Common Stock
    Market Newswire · 2026/9/23
  • Company notice
    Teva Pharmaceutical Industries | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-The Phoenix Holdings Ltd.(4.83%)
    SEC · 2024/4/9
  • Rating change
    Goldman Sachs Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $50
    Market Newswire · 2026/9/3
  • Rating change
    Jefferies Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/9/3
  • Rating change
    Piper Sandler Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $44
    Market Newswire · 2026/8/27
  • Rating change
    J.P. Morgan Sticks to Their Buy Rating for Teva (TEVA)
    TipRanks · 2026/9/25
  • Company notice
    Teva Pharmaceutical Industries | SC 13G: Statement of acquisition of beneficial ownership by individuals-The Phoenix Holdings Ltd.(5.40%)
    SEC · 2024/2/1
  • Rating change
    UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $48
    Market Newswire · 2026/9/4
  • Rating change
    Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $42
    Market Newswire · 2026/8/12
  • Rating change
    Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
    Market Newswire · 2026/9/3
  • Company notice
    Teva Pharmaceutical Industries | 4: Statement of changes in beneficial ownership of securities-Officer McAvoy David R.
    SEC · 2024/3/6
  • Rating change
    Scotiabank Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $40
    Market Newswire · 2026/9/3
  • BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $43
    Market Newswire · 2026/9/24
  • Rating change
    Leerink Partners Initiates Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Announces Target Price $45
    Market Newswire · 2026/9/9
  • J.P. Morgan Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
    Market Newswire · 2026/9/25
  • Rating change
    UBS Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $42
    Market Newswire · 2026/8/7
  • Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 A.m. ET
    GlobeNewswire · 2026/9/24

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 08:25:10 · For reference only, not investment advice and not tailored to your situation.